Dear Reader,
Picture this:
You get an email on Friday telling you to buy a little-known biotech stock you’ve never heard of...
On Monday you wake up to a takeover announcement at 6:30 a.m.
It turns out this tiny stock got bought out by a major pharmaceutical company.
The stock reprices almost instantly…
And suddenly you’re sitting on a 78% gain…
Locked in before you've had your coffee.
That’s not a hypothetical.
That’s what happened with Loxo Oncology…
A tiny biotech firm I recommended to my readers on a Friday.
On Monday morning at 6:30 a.m., Eli Lilly announced buying out the entire firm...
That's how my reader Scott S. was able to lock in a $19,275 gain in just three days!
“That was the fastest $19,275 I have ever made in my life. You recommended Loxo Friday morning and it was taken over Monday. Wow.”
It happened again with an obscure biotech firm called Tesaro.
You could have simply bought this stock when I issued a BUY recommendation…
Woke up to a takeover announcement at 7:04 a.m…
And cashed in a 91% gain that same morning.
Or Array Bio, another biotech company I recommended to my readers.
All you had to do was log in to your brokerage account and click the “BUY” button during regular trading hours…
And when Pfizer announced buying this firm at 6:45 am…
Once again, you could’ve seen a 148% gain in one morning – before lunch time!
Most Americans don’t even realize these early morning windfalls are possible.
And that’s a shame.
My name is Dylan Jovine, and I've been a professional investor for over 35 years.
I was one of the youngest people in America to start their own brokerage firm - at just 26 years old…
And let me tell you:
Biotech is the only sector I know where a stock can hand you years' worth of gains overnight.
Those three takeovers weren't luck.
They weren’t one-offs.
They landed inside what I call a “buyout window.”
Now, what does that mean?
Every so often, due to conditions I'll explain in a moment, deal activity in biotech surges.
Big Pharma is FORCED to open its checkbook...
Buy out a number of tiny biotech firms…
And those stocks take off virtually overnight.
That's a buyout window.
And it can generate countless early-morning windfalls for investors.
It all comes down to simple mathematics:
See, when Big Pharma buys a company, it can't pay the market price.
Think about it.
If a stock trades at $16, no shareholder hands over their shares for $16.
Why would they?
So the acquirer has to pay a premium. 30%... 50%... sometimes 100% or more above the market price.
And here's the part that matters for you:
The moment the buyout is announced, the stock reprices to the offer - almost instantly...
All you have to do is get into these firms…
Wait for the takeover announcement - they usually come before the market opens at 9:30 am…
And cash out potential windfall gains.
And here’s why some of Wall Street’s biggest players are piling into biotech as we speak:
We’re About To Enter The Biggest Buyout Window In Biotech History
Goldman Sachs predicts this buyout window could deliver a "record-breaking year" for pharma and biotech M&A...
“Biotech stands out as the only subsector working for now, supported by [...] a robust M&A pipeline that is on track for a record year.”
I think that's understating it.
For reasons that will become clear in a second…
I believe biotech is about to enter the biggest buyout window in market history.
And when it does, I expect a new set of winners to soar 40%... 75%... 135%... even 700% in a single day.
That's what makes biotech different from any other corner of the market.
During a buyout window you have a rare chance to compress years, potentially decades worth of stock market gains into a single day…
Now — some folks might read this and be skeptical…
They might say: "Dylan... if biotech is such a massive opportunity... why am I not hearing about it anywhere?"
It's a fair question.
Turn on CNBC or Fox Business and all they talk about is the next hot AI stock…
Microchips…
Data centers in space…
Nobody is talking about biotech.
But here's what 99% of investors don't realize yet…
Biotech Is Quietly Outperforming the Broader Stock Market
The S&P 500 has gone up a bit under 22% over the past 12 months…
Which is an incredible performance!
Historically, the S&P 500 delivers 10% per year.
But if you look at Biotech – the numbers are even more impressive.
The S&P Biotech ETF XBI has delivered an incredible 73% gain over the past 12 months!
That means biotech stocks have performed more than three times better than the broader stock market over the past 12 months.
And it's still nowhere near where it was in 2021.
If you look at IPOs, the difference is even more shocking.
Did you know the best performing IPO this year was NOT SpaceX…
Not a hot semiconductor firm…
Not a data center firm… either?
No.
It's a biotech firm called Veradermics.
This obscure firm uses AI for drug development…
And shares have surged 500% since its IPO.
Making it the best performing IPO of the entire year!
“Drug company Veradermics Inc. is up over 500% since its February debut, making it the best-performing U.S. IPO from any sector this year.”
In fact, biotech IPOs have trounced every other stock market sector this year!
But I'd bet money you have never heard about that.
99% of investors have no idea there’s a raging bull market in biotech right now.
And honestly?
I'm thrilled about that.
Because the reason they refuse to talk about biotech is simple…
Here’s Why You Will NOT Hear About This Hidden Biotech Boom
on Fox News or CNN Business…
The entire biotech sector has been through a brutal winter.
After a peak in 2021, biotech crashed — and it never fully recovered.
So the mainstream media lost interest…
And started chasing the “hot” stocks of the day - AI.
But here's what most people are missing…
Even in the depths of that winter — we saw a buyout window crack open.
In 2023 and 2024, while the headlines ignored biotech completely, Big Pharma quietly went on a buying spree.
Almost a quarter of a trillion dollars changed hands…
115 tiny biotech firms got bought out…
And my readers had a chance to profit all along the way.
They had the chance to see ImmunoGen hand them 449% — when AbbVie bought it out.
Altimmune: 150%.
We made money on “regular” biotech stocks that didn’t get acquired, too…
Like Viking Therapeutics, which soared 190% after my recommendation.
All during the so-called "biotech winter."
All while the mainstream media left this sector for dead.
That was the window creaking open a few inches.
And my research indicates this window is about to get blown off its hinges…
Again, I'm willing to put my entire reputation on the line here…
And say this buyout window will be the biggest in the history of biotech.
Because right now, for the first time I've ever seen, three enormous forces are converging on this beaten-down sector at the exact same moment.
I'll walk you through all three in just a moment.
And I'll show you three stocks that could hand you windfall gains virtually overnight.
Now, to be clear: this isn't a future prediction. It's already happening:
When a buyout window cracks open, Big Pharma goes on a massive takeover spree…
And that's already started.
In the past few months alone:
- AbbVie acquired Apogee Therapeutics in a $10.9 billion deal - shares soared 60% in a day…
- Day One Pharmaceuticals surged 65% in a day after getting acquired by Servier…
- And when Vertex acquired Crinetics Pharmaceuticals in a $10 billion buyout - its biggest buyout ever - shares popped 101% in a single day…
These aren't cherry-picked stories from some golden age long past.
This is happening right now, this quarter, while the financial media looks the other way.
And while most investors have no idea what's happening… The smartest investors on the planet are getting positioned to cash in on this historic buyout window.
This Biotech Takeover Handed Wall Street A 100-Bagger!
Take Baker Brothers for example…
A legendary biotech fund that bought into a small cancer company called Seattle Genetics back in 2003.
Shares traded for $2.25 at the time.
In 2023, Pfizer paid $229 a share to buy the entire company.
That's a 100-bagger.
Baker Brothers owned nearly a quarter of the firm. Their stake paid out roughly $10 billion.
And you could've invested alongside them.
I call these insiders the “Biotech Buffetts”...
And right now, they're quietly piling cash into biotech at an unprecedented pace.
Even tech billionaires are getting into the mix.
OpenAI founder Sam Altman...
Mark Zuckerberg…
Peter Thiel…
Marc Andreessen…
These billionaires have over $10 billion invested in biotech.
OpenAI has even seen researchers leave to pursue a new AI-powered biotech venture.
“Several OpenAI researchers expected to join new biotech venture.”
These folks are all in position to take advantage of a historic buyout window…
In fact, the Financial Times reports that hedge funds have already been minting "huge profits" off this biotech rally…
“Biotech rally mints huge profits for hedge funds.”
All while the little guy has been sidelined!
Because, by the time you hear about this “hidden” biotech rally on the mainstream media…
It will be too late.
All the big gains will be off the table.
That’s why I’ve prepared this urgent presentation.
Because I want you to get a chance to profit.
I have identified three tiny biotech firms that could be next in line for outsized gains.
My research indicates that these types of firms can surge 40%... 75%... 135%... In rare cases even 700% in a single day!
And I'm urging you to take advantage.
Because we're not just talking about the chance here to cash in some quick gains…
We're talking about an opportunity to change your financial trajectory forever…
And outperform the broader market by a wide margin.
Now, what does that mean specifically?
During Biotech’s Last Buyout Window We Locked in an Average 52.9% Gain per Trade – Winners and Losers!
Let me put it like this…
I had my team go through my entire track record…
Every position I closed during the last buyout window in 2023 and 2024…
That includes both winners and losers.
The result?
Had you followed my research, you could’ve locked in an average 52.9% per trade.
To put that into perspective…
Across 2023 and 2024, the broader biotech sector delivered just 8.7%.
In other words...
We outperformed the entire sector by over 6X!
During a “biotech winter” as biotech as a whole underperformed.
Let that sink in.
While the mainstream media had left this sector for dead...
While Wall Street called it a "biotech winter"...
The average trade in our book — winners AND losers — outperformed the broader biotech sector by over 6X.
That's not a hypothetical built on my three best trades.
That's the average across every closed trade in the book during that stretch — both winners and losers.
How often do you get a chance like that?
To cram years worth of stock market gains into a very short window of time?
That's why investing during this buyout window can be so powerful.
Because think about it…
If you're outperforming the market by such a wide margin…
You Can Reach Your Financial Goals So Much Faster
See, Wall Street tells you, investing is difficult.
Buy quality names…
Hold them for years…
And there’s nothing wrong with that, if you’re happy with your average 10% returns per year.
But look, I’m not a young man anymore…
I simply don’t have decades to wait around...
And maybe you feel the same way.
The good news is, you don’t have to.
Because, during a buyout window, you can compress years… potentially decades worth of “normal” stock market gains into weeks or just days.
And my research indicates we’re about to enter the biggest buyout window in biotech history.
Now look, I've been doing this for 35 years.
So I know some readers might be skeptical.
And you should be — that skepticism has probably saved you a lot of money over the years.
But here's the thing...
The buyout window in 2023-2024 wasn't a one off.
We've seen buyout windows in biotech before.
And each time one opens, the same thing happens:
A whole series of tiny, ignored stocks double and triple in days and weeks...
A handful begin runs that turn into generational wealth...
And the folks who got in before the window opened had the chance at some of the biggest gains of their lives.
We saw this in 2015.
Big Pharma went on a historic buying spree...
AbbVie acquired Pharmacyclics in a $21 billion deal…
Shares surged 110% in the run-up to the acquisition…
When Shire Pharma bought out Dyax, shares popped 30% in a single day…
And when Alexion acquired Synageva, shares exploded 115% in a single day…
That's the power of the buyout window.
Now, some folks might look at gains like this and think "that's too good to be true"...
They might think it takes luck to hit numbers like that…
But as I mentioned to you before…
When big pharma buys out a tiny biotech firm they have to pay a premium…
They have to pay more than stocks are trading for - or no shareholder would sell theirs.
So the key is to get in before the takeover is official…
Wait for the takeover announcement – which often comes before the market opens at 9:30 am in the morning…
And potentially cash in windfall gains.
That’s how my reader Jason H. was able to see a $22,000 profit when Array Bio got bought out by Pfizer.
“I made $22,000 when Array was taken over. [Dylan] really is AMAZING!”
It’s incredible.
That's how lucrative these biotech takeovers can be.
One buyer with a checkbook resets the price of your shares in a single morning.
And as I'm about to show you…
During a buyout window, pharma giants are FORCED to buy up tiny microcaps…
Potentially dozens and dozens of them.
Are you starting to see how we were able to outperform the broader biotech market by such a wide margin during the last buyout window?
We saw it happen again in 2019.
Another buyout window opened.
Same story, big pharma giants went on another huge shopping spree…
And my readers had a chance to see windfall gains again.
For example, when GSK bought out Tesaro, my readers had a chance to lock in a 91% gain by lunch time…
Reader Karen A. says she made incredible gains in just three weeks off that trade.
“Dylan, thank you for sharing your ideas with us. Tesaro was a great tip. I made incredible gains in 3 weeks from it. Your help is very much appreciated. Thanks!!”
Or Loxo Oncology.
When Eli Lilly bought out this firm, we cashed out a 78% gain.
My reader Mike K. says he cashed out from Loxo in just three days.
“Unbelievably prescient market analysis and insanely profitable investing ideas. One stock I owned (Loxo) soared in 3 days giving me an insane profit.”
In some cases, we were able to make money twice on the same stock!
I recommended ChemoCentryx and my readers had a chance to see up to a 300% gain.
And then I recommended it AGAIN before Amgen bought out the firm…
And my readers had a chance at another 163% gain.
And to be clear…
Every trade I just named is a real, closed recommendation from my published track record.
These are not hypothetical gains, that could have or should have happened under perfect conditions…
These are all real gains that real people had a chance to make.
The Real Biotech Boom Hasn't Even Kicked Off Yet…
Now, if you've missed out on these windfalls – don't worry.
To my knowledge, the mainstream media has never discussed what a buyout window is…
Or why it can create such incredible returns for investors.
That's why I prepared this urgent presentation…
Because, again…
My research indicates that we’re about to witness the biggest buyout window in biotech history…
It will put these prior windows from 2015, 2019, and 2023-2024 to shame.
And I believe it will hand clued-in investors a historic profit opportunity.
We could see dozens of biotech firms get acquired and make their investors windfalls.
Why?
Because, right now, three forces are converging that will FORCE pharma giants to open their pocket books…
And buy out more tiny biotech firms than ever before in history.
Yes, you've read that right…
Why Big Pharma Is FORCED To Buy Out Tiny Firms During A Buyout Window…
So what forces the checkbook open?
I told you three forces were converging on biotech.
Let me show you the first two right now.
Force #1: The largest patent cliff the drug industry has ever faced.
Here's something most investors don't understand about Big Pharma.
Every blockbuster drug is protected by a patent.
And when that patent expires, every competitor is allowed to flood the market with cheap knockoffs.
Now, what does that mean for the patent holder?
Of course, their revenues plummet!
We've seen this happen over and over again.
When Pfizer's Lipitor lost its patent, sales of this drug collapsed 71% in a single year.
Pfizer's profits got cut in half!
“Pfizer Profits Halved As Lipitor Comes Off Patent”
Or when AbbVie lost its patent for Humira – a huge cash cow for its business…
Humira used to generate over $21 billion in sales per year.
After the patent expired?
Sales dropped to only $9 billion – a near 60% drop.
Or Sanofi's bloodclot-medication Plavix.
After the patent expired, Sanofi reported that U.S. sales cratered by over 97%!
Industry insiders call this a "patent cliff".
And that's why I had to rush this urgent presentation out to you…
Because here's the reality…
The Biggest Patent Cliff in Biotech History…
In the next four years alone, more cash-cow drugs will lose their patent protection than ever before in biotech history.
Medical Daily calls it "the most dramatic patent cliff in history"...
“Between 2025 and 2030, the pharmaceutical industry faces its most dramatic patent cliff in history.”
And that's a HUGE problem for Big Pharma.
Take Merck's cancer drug Keytruda for example...
It's the best selling drug on earth, with almost $30 billion in sales per year.
That's nearly half of Merck's entire business – from ONE drug…
Merck and Pfizer alone could lose $400 billion in revenue if competitors knock off their drugs.
“Pfizer and Merck are facing looming patent cliffs which will expose $400 billion of sales to cheaper competition.”
So pretend you're the CEO of Merck.
The clock is running.
Within the next two years you could lose a major cash cow.
And you cannot invent a replacement blockbuster fast enough…
Because drug development takes a decade or more.
So, what do you do?
You buy up as many biotech startups with a promising new cancer drug as you can…
Hoping to find a replacement blockbuster drug to make up for the loss.
That is exactly what's driving this huge M&A boom in biotech.
As Reuters puts it, this patent cliff is about to usher in a "mega year" for big pharma takeovers.
“Big Pharma M&A set for mega year as patent expiries drive deal urgency”
That's force #1.
And before we move on to force #2, there's something you have to realize:
We're talking about hundreds of billions of dollars that are at stake for Big Pharma…
So when they're FORCED to buy out tiny biotech firms to replenish their drug pipelines or risk losing them to competitor buyouts…
These pharma giants don't mess around.
They routinely pay huge premiums…
And that has created incredible profit opportunities for investors.
For example, when Pfizer acquired Arena Pharmaceuticals, shares soared 80% in a day…
When BioMarin bought Inozyme Pharma to expand its rare-disease pipeline...
Shares soared 178% in a single day.
And when Pfizer bought out Trillium Therapeutics, shares exploded 188% in a single day…
In some cases, the gains can become almost absurd.
When Allergan acquired Tobira Therapeutics, shares in this tiny startup exploded as much as 700% in a single day!
700%!
You can see the massive spikes in those charts.
They go straight up.
As I told you before…
When Big Pharma whips out its check books, these stocks get repriced virtually instantly.
That's the power of the buyout window.
Investors who bought those firms had a chance to cram years… even decades worth of stock market gains into a single day.
And I believe the upcoming buyout window could get even bigger.
Because, again, there's three forces converging on this sector right now.
So far we've only discussed force #1 – the patent cliff.
Which brings us to Force #2…
The Biggest War Chest Big Pharma Has Ever Assembled…
Look, obviously you can't go shopping if you don't have any money.
For a historic buyout window you need loads and loads of cash.
And here's the good news…
Big Pharma's pockets are fatter than they've ever been.
By a wide margin!
According to Ernst & Young, Big Pharma is sitting on $1.37 trillion in firepower for this upcoming buyout window alone.
“Despite its increased M&A investment, the industry still commands more than US$1.37t in dealmaking capacity – higher than at any point in the history of the Firepower report apart from 2022.”
And that's just the top pharma firms.
You add the broader life sciences industry into the mix, and these firms are sitting on a combined firepower of $2.1 trillion…
According to Ernst & Young it's the biggest war chest in biotech history!
“With a record US$2.1 trillion in Firepower, the life sciences sector is prepared to accelerate dealmaking into 2026 and beyond.”
So think about that for a second…
You've got the biggest patent cliff in biotech history…
And the firms facing it are sitting on more cash than ever before…
There is only one place all that money can go:
Down the food chain…
Into the small biotech companies that own the drugs, the pipelines, and the science Big Pharma now desperately needs to survive.
Are you starting to see why I call this the biggest buyout window in biotech history?
And to be clear…
That is NOT a prediction.
It's already happening.
Right now.
In fact…
We're Already Seeing a Record Number of Biotech Acquisitions In 2026
Big Pharma's shopping spree has already started.
This year alone…
- Merck bought out Terns Pharmaceuticals in a $6.7 billion deal…
- GSK agreed to buy Nuvalent for $10.6 billion – its largest deal in over a decade…
- Eli Lilly alone signed roughly eleven deals worth about $25 billion in the first half of this year…
Altogether, we've seen 37 biotech buyouts valued over $1 billion this year…
That's an all-time record!
That's why the Financial Times reports that...
“Big pharma groups are snapping up biotechs at a record pace.”
Oldenburg Capital calls it...
“The combination of strategic urgency, tighter private funding, and an uncertain IPO market has created the perfect environment for accelerated dealmaking.”
That's the buyout window starting to crack open.
And remember — that's with only two of the three forces in play.
So far, we've discussed the biggest patent cliff in biotech history…
Meeting the biggest war chest in biotech history…
But it's the third force that will blow this buyout window wide open…
I believe it will create the biggest profit opportunity for biotech investors I've seen in my entire 35-year career.
We’re already starting to see M&A activity heat up…
And I want you to take full advantage.
Because here's the thing…
Almost DOUBLE Your Money By Lunch
With a normal stock, you wait.
You hope.
You watch it grind higher a few percent at a time, and you pray you're right over months or years.
A buyout doesn't work like that.
One buyer with a checkbook reprices the stock all at once.
That’s what happened with ImmunoGen…
A tiny biotech firm I recommended to my readers when it was trading for under $6.
The firm was developing a drug for ovarian cancer.
Shares started creeping up as the market got excited about this firm's new drug pipeline.
And then on November 30, 2023 – boom…
AbbVie announced buying ImmunoGen for over $31 per share…
Shares jumped 83% in a day once the news broke.
Overall my readers had a chance to lock in a 449% gain on ImmunoGen…
That's enough to turn a $10,000 stake into $54,900, before fees and taxes.
And, once again, during a buyout window, you're not just talking about ONE takeover…
You get an entire flood of them.
I just issued BUY alerts on three stocks that are poised to soar next…
Every single one of them could hand you windfall gains – virtually overnight.
That's why I keep telling you the buyout window is unlike anything else in the market.
Because you don't need to wait around for years to see significant gains.
You don't need to trade in and out.
You don't need to time the market or watch the ticker all day.
All you need to do is buy the right company before the phone rings.
And I want to be clear about what that actually means.
You cannot buy in after the call.
When Eli Lilly bought Loxo, that stock repriced at 6:30 in the morning. The market wasn't even open.
Nobody got to think it over.
Now, in case you're wondering…
"But Dylan, out of thousands of biotech companies, how do you know which ones get the call?"
That's a great question.
And the answer is simple…
A 35-Year Track Record of Picking Winning Biotech Takeovers
See, I've been a professional investor for 35 years.
I’ve shown my readers countless profit opportunities over the years.
I recommended Palantir at $7 - before it soared as high as 2,712%.
Rocket Lab at $3 - before it climbed as high as 3,874%.
And Micron at $54 - before it ran as high as 2,208% at its peak.
However, one of my specialties is picking lucrative takeover stocks right before they get acquired.
Early on in my Wall Street career I was so good at finding these stocks before they got bought out…
My Wall Street clients bankrolled me to start my own brokerage firm – at just 26 years old.
I was one of the youngest people in America to do that.
I'm not telling you that to brag.
I'm telling you, because after 35 years I've developed a simple framework to find biotech stocks that are right on the verge of getting bought out.
And to be honest with you…
I don't use a supercomputer.
I don't have a secret algorithm or some black-box "AI system" I can't explain.
You've probably seen those pitches - “trust the mysterious machine, don't ask how it works.”
That's not me.
Instead, I developed a simple checklist to spot hot candidates for a takeover.
I look for three specific criteria.
Because these are the exact traits that make Big Pharma pull out its checkbook and make the call.
And I'll give you my entire blueprint right now…
My Billion-Dollar Buyout Checklist Revealed
Here's all you need to find a winning biotech stock:
Ingredient #1 — A strong patent pipeline.
You want a company with a breakthrough product that has real demand…
And that's protected by strong patents.
When you find that, it's like owning a gas station in the desert.
Ideally, you want a firm that owns multiple of those.
That's what got me excited about ImmunoGen…
ImmunoGen owned a proprietary technology called Antibody Drug Conjugate.
Think about it like a smart bomb for cancer.
AbbVie wanted this technology so bad, they ended up buying ImmunoGen for $10.1 billion.
And handed my readers a 449% gain…
That's where I start.
Ingredient #2 — A strategic partner already at the table.
The second thing I look for is a strategic partner.
Not just an investor - a business partner.
A big pharmaceutical company already working alongside the little one.
See, most biotechs are run by scientists and academics.
Brilliant people - who often know nothing about selling a drug across the globe.
So when a giant like Novartis or Pfizer partners with a tiny biotech, it's saying: we like this science, and we can sell the heck out of it.
Now think about what that tells you as an investor.
A partnership is almost like a buyout with the paperwork half-finished.
The pharma giant is already inside the building.
It's already seen the data.
When the checkbook comes out, big pharma goes for the firms it already knows and trusts.
That's exactly what happened with ChemoCentryx…
They had a strategic partnership with Vifor Pharma…
Which eventually grew into an ownership stake…
And handed my readers a 163% gain on a silver platter.
That's Ingredient #2.
And finally, there's…
Ingredient #3 - A drug the FDA has already signed off on, or a first-in-class therapy no one has cleared before.
Here's the ugly truth about biotech – and why some people try to steer you away from it:
Most drugs fail.
The graveyard is full of "breakthroughs" that looked incredible — right up until the FDA said no.
So when a small company actually gets a drug across the finish line…
A real FDA approval, or better yet, a first-in-class therapy the agency has never cleared before…
The science isn't a theory anymore. It's a product.
And that's the exact moment a biotech goes from "interesting" to "irresistible" for Big Pharma.
Because these big firms can't wait around for years when they're facing a patent cliff…
They need approved, selling drugs — now.
And the fastest way to get one is to buy the company that already has it.
That's what happened with Krystal Biotech.
In 2023, Krystal won FDA approval for the first-ever redosable gene therapy…
A landmark treatment for a devastating genetic disease no one had ever been able to treat before.
And readers who followed my recommendation to buy Krystal Bio had a chance to lock in an additional 88.1% return...
After already locking in 242%.
That's what an FDA stamp does.
It takes the biggest risk off the table - and paints a target on the company's back.
So there you have it…
That's the whole game: strong patent, strategic partner, and a drug the FDA has blessed.
It might sound simple…
But that's the entire blueprint that has helped me identify dozens and dozens of winning biotech takeovers over the past 35 years.
Run a company through those three filters, and you're no longer guessing which biotech might pop someday...
You're identifying the specific companies that are high up on Big Pharma's shopping list.
And I have identified three biotech firms that I believe will do very well in the weeks and months ahead…
Now, before I tell you all about them…
There's one more reason why I believe this upcoming buyout window will be bigger than any prior window in history.
Because there's three forces converging on biotech right now.
So far, we've only discussed two.
A historic patent cliff and a record war chest for acquisitions.
But there's another one we haven't touched on yet...
And it's what makes this such a once-in-a-career opportunity…
Force #3:
The Greatest Buyer’s Market in Biotech History
Again, I’ve been identifying lucrative biotech stocks for 35 years now.
In all this time, I have never seen a situation like today.
Usually, it would be extremely rare for a drug company to trade for less than the cash sitting in its own bank account.
In all of 2019, there were 34 of them.
By 2021, there were 173.
And through last year, roughly a third of every listed biotech in America was trading below the cash in its own bank account.
“Record Number of Small Companies Trading Below Cash.”
Think about that.
That’s like somebody offering you a $100 bill for $90.
For investors, it’s a dream come true.
Even with the biotech sector rallying 73% over the past 12 months, all these stocks are still trading under their cash value.
So think about that.
Big Pharma is facing the biggest patent cliff in history…
They’re sitting on the biggest war chest in biotech history…
And they’re looking at the cheapest valuations we’ve seen in years.
Do you see why I’m pounding the table?
Why I consider this the biggest biotech opportunity in my 35-year career?
And it is already starting.
Big Pharma giants are already falling over themselves to snap up as many biotech firms as they can.
Investment Banking firm Centerview Partners says:
"It's the liveliest market I've ever seen"
Eric Tokat, Co-President of Centerview PartnersAnd the Financial Times predicts:
“2026 is shaping up to be the strongest year for biotech M&A in a decade.”
We've already seen more billion-dollar buyout deals in biotech this year than at any point in history.
This historic buyout window could mint an entire new class of millionaires.
But unfortunately, most investors will miss out on this historic boom.
Why?
Because by the time you read about all this in the mainstream financial media, it will be too late.
I don't want you to miss out.
I want you to take full advantage.
And I want you to ride this historic boom for the chance to change your financial trajectory forever.
Now, I've given you my entire billion-dollar buyout checklist.
I've shown you exactly how I've been spotting biotech buyout candidates for 35 years now.
You could simply take this information and go hunting for the next takeover target yourself.
But with thousands of biotech firms in the U.S. alone…
It would probably take you weeks, if not months.
You'd need an entire team to do it.
And you'd need access to data feeds that can cost tens of thousands of dollars per year.
If you have all that, who knows… you might find the next big winner yourself.
Or, and this is what I suggest…
Simply let me do all the heavy lifting for you.
Buy These 3 Top Biotech Stocks Today
I ran the entire biotech sector through the same three-part checklist I showed you earlier…
Strong patents, a strategic partner already at the table, and a drug the FDA has already signed off on, or a first-in-class therapy the agency has never cleared before.
After weeks of research, three firms emerged above everything else.
And I'd like to tell you all about them...
The Keytruda Killer — This one could provide Merck's next cash cow
Remember how we discussed Keytruda earlier?
It's the best-selling medicine on Earth.
It generates nearly half of Merck's revenue.
And their patent expires in 2028.
It's at the center of this historic patent cliff.
And Merck is desperate to replace it ahead of losing their patent on it.
Now, here's the thing…
There's a publicly traded biotech firm that has already beat Merck's Keytruda in clinical trials.
They own the rights to a new type of drug that's making huge waves in biotech right now.
In fact, in a Phase 3 lung-cancer trial, this company's therapy went toe-to-toe with Keytruda and came out so far ahead….
Analysts say this new drug could be "one of the game changing molecules in immuno-oncology".
And Nature.com says it could be:
“...the first direct challenge to Merck's behemoth”
This new product is such a threat to Merck's Keytruda…
When this biotech firm released its Phase 3 trial results, Merck's stock got dumped.
About $6 billion in value got wiped out almost instantly.
That's how powerful this new Keytruda competitor is.
Think about the position that puts Merck in.
By 2028, they could lose a $30 billion cash cow…
And this biotech firm owns the solution.
Merck has already been on an acquisition spree lately...
They've spent roughly $29 billion buying out biotech firms to prepare for Keytruda's patent expiration.
And I believe it's only a matter of time before they snap up this firm too.
Best of all, it's still flying under the radar.
You can scoop up shares for $15.
But it likely won't stay that cheap for long.
So I urge you to take a position right away.
Not tomorrow, not next week…
Today!
That brings us to firm #2.
My #1 Biotech Takeover Target
It's a tiny oncology firm…
Small enough that a single buyout offer could reprice the entire stock overnight.
In a way, this reminds me a lot of ImmunoGen before it handed my readers a 449% gain.
Because this tiny biotech firm just did something almost no company its size ever pulls off:
It's the first firm to bring a new type of blood cancer drug to market.
We're not talking about promising trial results here.
This firm's new drug has full FDA approval…
It just hit the market a few months ago and revenues are ramping up.
This tiny biotech firm received backing from one of the biggest drugmakers in Japan.
They committed $1.5 billion to support this tiny firm's new cancer drug.
And here's the kicker:
This tiny firm is valued at under $1 billion.
In other words…
A major pharmaceutical company with billions of dollars in revenue took one look at this firm and decided to sign a deal that could be more valuable than its entire market cap.
That's huge!
It shows you how serious they are…
And I believe it's only a matter of time before this turns into a full-blown buyout.
This is another stock I recommend you buy ASAP.
Because this pharma conglomerate could make a move any day now.
And finally, there's biotech firm #3:
The Company Biogen Already Bought Half Of
Big Pharma has spent billions of dollars and fifty years to try and solve one problem:
How can a drug cross the blood-brain barrier?
It’s a small membrane in your skull that prevents medication from reaching the brain.
That’s why drugs for Alzheimer's and Parkinson's have all failed so far.
But one tiny biotech firm based out of San Francisco has finally cracked the code.
They built a delivery system that carries medicine across that membrane and into the brain.
And this isn't promising trial data.
The FDA already approved the first drug it delivered.
The agency's own drug evaluation chief called it "the first product approved to address neurologic complications" of Hunter syndrome.
And here’s the kicker:
Biogen, one of the biggest names in brain medicine, has already taken a 50/50 stake in this firm's Parkinson's program.
Why?
Because Alzheimer’s affects 55 million people worldwide.
And yet, there’s only about $6 billion in drug sales annually.
Deloitte calls it...
“One of the biggest gaps between patient need and commercial opportunity in medicine.”
But Biogen only owns half of one drug.
They don't own the delivery system.
And there's exactly one way to get it.
You can still pick up shares for around $22.
And I don't expect that to last.
This is another biotech firm I recommend you claim a stake in right away.
So how can you get started investing in these firms?
I've put full write-ups on all three into a brand-new research briefing called:
The Buyout Window: 3 Tiny Stocks Poised For 6am Windfalls
Inside, you'll discover all the details you need to get started right away.
The names, ticker symbols and an in-depth analysis of every one of these disruptive firms.
Again, these are my three top recommendations for the upcoming buyout window.
And to be clear: this report is not for sale anywhere, at any price.
But I'd like to rush you a copy with my compliments at no extra cost to you.
The only thing I ask in return?
Try out my VIP research service Biotech Insider.
Introducing:
Biotech Insider is the culmination of 35 years of experience.
Once a month I bring you a new investment idea with the potential for 10X gains or more. And you don't want to miss out. Because we've already had countless winners. Like, for example:
- 449% on ImmunoGen when AbbVie bought it out…
- 300% on ChemoCentryx, before Amgen swept it up…
- 242% on Krystal Biotech…
- 190% on Viking Therapeutics…
- 151% on Eli Lilly…
And many, many more.
Now, a lot of folks out there like to hype up their winners and hide their losers.
That's not me.
So here's a full disclosure of our track record:
Since I launched Biotech Insider in 2018, our average closed trade has returned 35.5% — winners and losers combined.
And that's including every loser in the book.
During the last buyout window in 2023-2024 we did even better…
Our readers had the chance to lock in an average 52.9% gain per trade!
Again, that’s both winners and losers.
You don't have to take my word for it.
Simply take a look at what our readers are saying:
“I was skeptical at first. I’ve been burned before. But I’m happy to report I made $5,645 in 71 days with Mirati Pharma. Thanks for helping.”
“Started reading your newsletter last December, got into Krystal. Very happy with the result. Great ideas! I’ve never felt so confident holding a position.”
“You are the best and most accurate investing advisor I have ever used — honest, kind, and trustworthy, far above all the other services.”
I love to receive notes like this.
And I hope that I'll be receiving a similar note from you soon as well.
Now, before I give you all the details on how to join Biotech Insider…
There's one more bonus report I'd like to get into your hands right away…
See, on December 18, 2025, Trump signed what's called the BIOSECURE Act.
Simply put, it created a "blacklist" of Chinese pharmaceutical suppliers.
If you source your drug ingredients from these firms…
You risk losing federal contracts, grants and loan funds.
There's only one problem…
79% of U.S. drugmakers rely on Chinese suppliers…
One of the firms on this blacklist touches one in four drugs Americans take…
That's why every American hospital, drugmaker and lab is desperate to find a replacement…
“Drugmakers race to find alternative suppliers as US cracks down on Chinese biotech.”
And I found the firm I believe is first in line to fill this gap in the market…
It's a U.S. based supplier that provides ultra-pure chemicals, single-use bioprocessing assemblies and medical-grade filtration systems.
This firm already provides 300,000 customer locations across 180 countries.
And fourteen drugmakers have committed $480 billion to build American factories.
Every one of them needs what this company sells.
And yet, this firm is still dirt cheap.
It's trading for under $12.
But I don't believe it will fly under the radar much longer.
And I'm not the only one…
The director just bought 50,000 shares on the open market.
This could be your last chance to get in while shares are still dirt cheap.
I've put all the information you need to get started in a bonus report called
The New American Titan
And I'd like to rush you a free copy as another welcome gift, when you try out Biotech Insider today.
So how do you get in?
As you might imagine, Biotech Insider is not cheap.
And that's by design.
It's the same research my members have used for years to get in front of buyouts before Wall Street wakes up.
That's why a full year runs $2,997.
However, since we're facing a truly historic buyout window…
I don't want price to be an issue.
I want regular investors positioned before this historic buying spree kicks into high gear…
Not reading about the historic wave of buyouts after the gains are gone.
That's why, through this presentation only, you won't pay $2,997.
You won't pay $2,500.
Your price today is just $1,997 for a full year.
And given what a single one of these picks can do, I think that's a steal.
Simply click the button below to get started.
Once you click it, you'll be taken to a secure enrollment page where you can lock in your $1,997 rate.
Plus, I have some additional bonus reports for you that we haven't even discussed yet.
So let me sum up everything for you.
Here's everything you get the moment you join Biotech Insider:
BONUS Report #1: The Buyout Window: 3 Tiny Stocks Poised For 6am Windfalls — ($1,997 value)
All three picks. Names, tickers, and exactly how to position in each.
The Keytruda killer…
My #1 takeover target…
And the company Biogen already bought half of.
This report alone could pay for your membership many times over.
BONUS Report #2: – The New American Titan ($500 value)
In December, Congress built a blacklist to cut China out of America's drug supply chain.
In June, the Pentagon added the biggest name on it — a manufacturer involved in roughly one in four drugs Americans take.
Now every one of its U.S. customers needs a replacement.
Inside: the American supplier already positioned to be it, with a catalog matching the law's own requirements line by line — and fourteen drugmakers committing $480 billion to build the factories that need exactly what it sells.
BONUS Report #3 — The End of Disease – The AI Company Revolutionizing Medicine — ($500 value)
There are 10,000 known diseases and only about 500 cures. The reason is math: the average drug takes 12 years and $2.6 billion to bring to market, so companies chase one disease at a time. This report shows you the technology that collapses that timeline from years to days, and names the small companies whose software Pfizer, Merck, AstraZeneca and Eli Lilly already run on.
It's the difference between waiting for the next cure and owning the machine that makes them.
You'll have it in your first ten minutes as a member.
BONUS Report #4 — The FDA Catalyst Calendar — ($500 value)
This is the one that makes you dangerous. A calendar — real dates, real companies — of the biotech catalysts scheduled to hit in the weeks ahead, the exact moments these stocks move fastest.
While everyone else reacts to the news, you'll be looking at the calendar before it happens. Your radar for the entire window.
A full year of Biotech Insider — ($2,997 value)
Every new pick I uncover. Every new takeover target I'm tracking. And my sell alerts — so you know exactly when to lock in your gains and walk away a winner.
That's almost $6,500 in research and reports — for $1,997.
And you risk nothing to find out if I'm right.
I don't want a penny of that unless you're convinced.
So here's my promise: join today, and you get a full 30 days to go through everything.
Read all four reports.
Look at every recommendation.
Follow my alerts.
If you decide Biotech Insider isn't everything I've promised and more…
Just call my team inside those 30 days.
You'll get a full refund of your membership fee and you keep every report you've downloaded.
They're yours to keep either way.
That's how confident I am in what's coming.
But you do have to decide now.
Because the clock is ticking.
Remember, you cannot buy these stocks after the announcement – or you miss out on the real windfall.
When Eli Lilly bought out Loxo, that stock repriced at 6:30 in the morning.
The market wasn't open. Nobody got a chance to think it over.
Scott S. made $19,275 on that trade because he was already holding when the phone rang.
So this isn't a choice between buying now and buying later.
It's a choice between holding these three companies on the night it happens…
Or reading about somebody else's morning.
We are facing what I consider the biggest buyout window in biotech history.
We've already seen a historic amount of billion-dollar buyouts this year.
We've already seen biotech IPOs outperform every other IPO sector (including stocks like SpaceX!)
And we've already seen Biotech stocks start to take off…
Including AbiVax, which soared over 1,200% in recent months…
And Veradermics which is the best-performing IPO of the entire year.
But the real action is just about to begin.
Remember, Big Pharma is facing the biggest patent cliff in history…
Sitting on the biggest war chest it has ever assembled…
And looking at the biggest buyer’s market in biotech history…
Mark my words:
I believe all these three forces combined will unleash the biggest wave of acquisitions we have ever seen in biotech.
And the three stocks I have identified are first in line for a buyout.
Simply put, this is the biggest biotech opportunity I've seen in my 35-year career.
So click that button to get started:
At this point, the only question is…
Are you in?
Or are you out?
I can't make that decision for you.
But I'm sure you'll make the right call for yourself and for your family.
But remember, Big Pharma has already started its historic acquisition spree…
And you don't want to miss out on the biggest buyout window this market has ever seen.
